145 related articles for article (PubMed ID: 21734474)
21. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
22. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
23. Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Baek MH; Park JY; Rhim CC; Kim JH; Park Y; Kim KR; Nam JH
Gynecol Obstet Invest; 2017; 82(4):329-339. PubMed ID: 28125812
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
26. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
[TBL] [Abstract][Full Text] [Related]
27. Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.
Vandenput I; Capoen A; Coenegrachts L; Verbist G; Moerman P; Vergote I; Amant F
Int J Gynecol Cancer; 2011 Aug; 21(6):1071-7. PubMed ID: 21792013
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical evaluation and lymph node metastasis in surgically staged endometrial carcinoma.
Pilka R; Marková I; Dusková M; Procházka M; Tozzi M; Kudela M
Eur J Gynaecol Oncol; 2010; 31(5):530-5. PubMed ID: 21061794
[TBL] [Abstract][Full Text] [Related]
29. Prognostic importance of selected molecular immunohistochemical markers and DNA ploidy in endometrial cancer.
Kudela M; Pilka R; Lubusky M; Hejtmanek P; Dzubak P; Brychtova S
Eur J Gynaecol Oncol; 2012; 33(2):159-63. PubMed ID: 22611955
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer.
Shiino S; Kinoshita T; Yoshida M; Jimbo K; Asaga S; Takayama S; Tsuda H
Clin Breast Cancer; 2016 Aug; 16(4):e133-40. PubMed ID: 27268749
[TBL] [Abstract][Full Text] [Related]
31. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
32. Prognostic biomarkers in endometrial adenocarcinoma.
Stănescu AD; Nistor I; Potecă AG; Diţescu D; Comănescu M
Rom J Morphol Embryol; 2014; 55(4):1339-44. PubMed ID: 25611264
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma.
Vang R; Barner R; Wheeler DT; Strauss BL
Int J Gynecol Pathol; 2004 Jul; 23(3):223-33. PubMed ID: 15213598
[TBL] [Abstract][Full Text] [Related]
34. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
35. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia contributes to development of recurrent endometrial carcinoma.
Pijnenborg JM; Wijnakker M; Hagelstein J; Delvoux B; Groothuis PG
Int J Gynecol Cancer; 2007; 17(4):897-904. PubMed ID: 17359291
[TBL] [Abstract][Full Text] [Related]
37. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.
Dupont J; Wang X; Marshall DS; Leitao M; Hedvat CV; Hummer A; Thaler H; O'Reilly RJ; Soslow RA
Gynecol Oncol; 2004 Aug; 94(2):449-55. PubMed ID: 15297187
[TBL] [Abstract][Full Text] [Related]
38. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
39. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Jongen VH; Briët JM; de Jong RA; Joppe E; ten Hoor KA; Boezen HM; Evans DB; Hollema H; van der Zee AG; Nijman HW
Int J Gynecol Cancer; 2009 May; 19(4):670-6. PubMed ID: 19509570
[TBL] [Abstract][Full Text] [Related]
40. High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Wik E; Birkeland E; Trovik J; Werner HM; Hoivik EA; Mjos S; Krakstad C; Kusonmano K; Mauland K; Stefansson IM; Holst F; Petersen K; Oyan AM; Simon R; Kalland KH; Ricketts W; Akslen LA; Salvesen HB
Clin Cancer Res; 2013 May; 19(9):2331-41. PubMed ID: 23538402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]